Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 15/20 | 0.56 |
| ▸ | IMPDH1 | P20839 | 11/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1152769 | 1.00 | IMPDH2 (0.56) | IMPDH2IMPDH1KDM4EALDH1A1LMNA | |
| SCHEMBL7881557 | 1.00 | IMPDH2 (0.56) | IMPDH2IMPDH1KDM4EALDH1A1LMNA | |
| SCHEMBL8951739 | 1.00 | IMPDH2 (0.56) | IMPDH2IMPDH1KDM4EALDH1A1LMNA | |
| SCHEMBL8951531 | 0.90 | IMPDH2 (0.46) | IMPDH2IMPDH1KDM4EALDH1A1LMNA | |
| SCHEMBL1153121 | 0.90 | IMPDH2 (0.56) | IMPDH2IMPDH1KDM4EALDH1A1LMNA | |
| SCHEMBL1153118 | 0.90 | IMPDH2 (0.56) | IMPDH2IMPDH1KDM4EALDH1A1LMNA | |
| SCHEMBL8951542 | 0.90 | IMPDH2 (0.46) | IMPDH2IMPDH1KDM4EALDH1A1LMNA | |
| SCHEMBL1475854 | 0.89 | IMPDH2 (0.58) | IMPDH2IMPDH1KDM4EALDH1A1LMNA | |
| SCHEMBL1475856 | 0.89 | IMPDH2 (0.58) | IMPDH2IMPDH1KDM4EALDH1A1LMNA | |
| SCHEMBL7877375 | 0.89 | IMPDH1 (0.60) | IMPDH2IMPDH1KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0745075-B1 | 6-SUBSTITUTED MYCOPHENOLIC AND DERIVATIVES WITH IMMUNOSUPPRESSIVE ACTIVITY | SYNTEX LLC (US) | 2001-12-05 | — | — | EP | claimed |
| WO-1995022536-A1 | 6-SUBSTITUTED MYCOPHENOLIC AND DERIVATIVES WITH IMMUNOSUPPRESSIVE ACTIVITY | SYNTEX (U.S.A.) INC. (US) | 1995-08-24 | — | — | WO | claimed |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND | 2013-10-31 | — | — | US | disclosed |
| US-8475804-B2 | Compositions and methods for treatment of filovirus-mediated diseases | U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) | 2013-07-02 | — | — | US | disclosed |
| US-7915255-B2 | Metabolism-modulating agents and uses therefor | VERVA PHARMACEUTICALS PTY LTD (AU) | 2011-03-29 | — | — | US | disclosed |
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | ZALICUS INC. | 2011-02-03 | — | — | US | disclosed |
| US-20060106097-A1 | Metabolism-modulating agents and uses therefor | UNIVERSITY OF QUEENSLAND (AU) | 2006-05-18 | — | — | US | disclosed |
| EP-0745075-B1 | 6-SUBSTITUTED MYCOPHENOLIC AND DERIVATIVES WITH IMMUNOSUPPRESSIVE ACTIVITY | SYNTEX LLC (US) | 2001-12-05 | — | — | EP | disclosed |
| US-5554612-A | IMMUNOSUPPRESSANTS, VIRICIDES, ANTITUMOR AND ANTIINFLAMMATORY AGENTS | SYNTEX INC (US) | 1996-09-10 | — | — | US | disclosed |
| US-5536747-A | ENZYME INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1996-07-16 | — | — | US | disclosed |
| US-5525602-A | TREATING INFLAMMATORY DISEASES, PREVENTING ALLOGRAFT REJECTION, AUTOIMMUNE DISEASES | SYNTEX (U.S.A.) INC. (US) | 1996-06-11 | — | — | US | disclosed |
| WO-1995022536-A1 | 6-SUBSTITUTED MYCOPHENOLIC AND DERIVATIVES WITH IMMUNOSUPPRESSIVE ACTIVITY | SYNTEX (U.S.A.) INC. (US) | 1995-08-24 | — | — | WO | disclosed |
| US-5444072-A | Useful in treatment of autoimmune disorders, psoriasis, inflammatory diseases, rheumatoid arthritis | SYNTEX (U.S.A.) INC. (US) | 1995-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | IMPDH2 2041/4885IMPDH1 1995/4885KDM4E 4345/4885 |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | IMPDH2 2041/4885IMPDH1 1995/4885KDM4E 4345/4885 |
| US-20060106097-A1 | Metabolism-modulating agents and uses therefor | IMPDH1, IMPDH2, HADHB | IMPDH2 2/4885IMPDH1 1/4885KDM4E 2168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.